Dr Ratnayaka publishes study of CT1812 as a dry AMD treatment

Dr Arjuna Ratnayaka publishes new paper exploring the potential of CR1812, as a drug to help treat dry age-related macular degeneration:  Sigma-2 receptor modulator CT1812 alters key pathways and rescues retinal pigment epithelium (RPE) functional deficits associated with dry age-related macular degeneration (AMD) – PubMed